Download PDF
- Lanxess
- Overview
- Last Modified:
- May 27, 2025
- Company type:
- Public
- Industry:
- Chemicals
- Verified:
- No
- No of Employees:
- 10 001 - 50 000
- Stock Code:
- LXS
- Download
- Signed Health Status Declaration Form
- Turnover $50m + ?:
- Yes
- Headquarters:
- Cologne
- Public Interest Score:
- 750+
- Lanxess
- General Information
Description
LANXESS is a leading specialty chemicals company based in Cologne, Germany. It was founded in 2004 as a spin-off from Bayer AG. The company focuses on the development, manufacturing, and marketing of chemical intermediates, additives, specialty chemicals, and consumer protection products
In 2023, LANXESS reported sales of approximately EUR 6.7 billion and employs around 12,600 people across 32 countries. They are known for their innovative solutions in various industries, including automotive, agriculture, construction, and consumer goods
Pamela Knapp:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Rainier van Roessel:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Hans Van Bylen:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Heike Hanagarth:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Lawrence Rosen:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Hans-Joachim MĂĽller:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Rainier van Roessel:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Hans Van Bylen:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Heike Hanagarth:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Lawrence Rosen:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Hans-Joachim MĂĽller:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Subsribe/ Login to view details on company risk rating
5 Benchmark > 4 Excellent > 3Â Good > 2 Caution > 1 Risk
- Company Information
- Company System Number:
- 15307
- Founded Year:
- 2004
- Registration Number:
- 10009610 RC15
- Country:
- Germany
- Stock Exchanges:
-
- Frankfurt Stock Exchange
- Financial year end:
- December
- No. of Countries operations:
- 32
- Company Status:
- In Business
- Industry Sub Category:
- Chemicals
- Date listed on Stock Exchange:
- 31/01/2005
- Contact Information
- Business operation:
- LANXESS core business is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and consumer protection products. On the following pages you can find detailed information about the LANXESS product range.
- Primary office:
- LANXESS AG - Headquarter, Kennedypl. 1, 50679 Köln, Germany
- Additional Information
- Listed?:
- Yes
- Company secretary:
- Dhanya Santosh
- Reporting currency:
- USD
- ISIN number (12 digit):
FSE
DE0005470405- Authorised shares:
- Issued shares:
- 91 520 000
- No of shareholders:
- 1001 and more shareholders
- No of shareholders holding 20%:
- 0 shareholders
- Number of shares traded
- Per Year:
- Per Quarter:
- Per Month:
Material Subsidiaries/Associates
For a comprehensive list, please contact InsidEntity.
Credit Rating
| Name | Logo | Country | Headquarters | Rating |
|---|---|---|---|---|
| Moody's | ![]() | United States of America | New York | baa2 |
| S&P | United States of America | New York | BBB | |
| Fitch | United States of America | New York | BBB- |
Countries Operations/ Offices
Company Directors
Name
Nationality
Age
Role
Qualification
Directors Tenure
Name
Duration
Director Experience
Name
Experience
Company Auditors
Name
Date Appointed
Years
Name
KPMG
Date Appointed01/01/2017
Year9 years and 8 months
Company Past Directors
Name
ED/NED
Role
Company Committees
|
Committee
|
Abbreviation
|
|---|---|
|
Supervisory Board
|
SB
|
|
Board
|
BD
|
|
Risk & Compliance
|
RC
|
|
Audit
|
AU
|
|
Remuneration
|
RE
|
|
Capital investment
|
CI
|
|
Industry Specific
|
IS
|
|
Nominations & Governance
|
NG
|
|
Health, Safety & Environment
|
HS
|
|
Social & Ethics
|
SE
|
|
Technology
|
TE
|
|
Executive
|
EX
|
|
Other
|
OT
|






